Mostrar el registro sencillo del ítem

dc.contributor.author
Gissler, Mark Colin  
dc.contributor.author
Stachon, Peter  
dc.contributor.author
Wolf, Dennis  
dc.contributor.author
Marchini, Timoteo Oscar  
dc.date.available
2023-07-19T15:40:56Z  
dc.date.issued
2022-02  
dc.identifier.citation
Gissler, Mark Colin; Stachon, Peter; Wolf, Dennis; Marchini, Timoteo Oscar; The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis; Frontiers Media S; Frontiers in Cardiovascular Medicine; 9; 826630; 2-2022; 1-17  
dc.identifier.uri
http://hdl.handle.net/11336/204466  
dc.description.abstract
TNF receptor associated factors (TRAFs) represent a family of cytoplasmic signaling adaptor proteins that regulate, bundle, and transduce inflammatory signals downstream of TNF- (TNF-Rs), interleukin (IL)-1-, Toll-like- (TLRs), and IL-17 receptors. TRAFs play a pivotal role in regulating cell survival and immune cell function and are fundamental regulators of acute and chronic inflammation. Lately, the inhibition of inflammation by anti-cytokine therapy has emerged as novel treatment strategy in patients with atherosclerosis. Likewise, growing evidence from preclinical experiments proposes TRAFs as potent modulators of inflammation in atherosclerosis and vascular inflammation. Yet, TRAFs show a highly complex interplay between different TRAF-family members with partially opposing and overlapping functions that are determined by the level of cellular expression, concomitant signaling events, and the context of the disease. Therefore, inhibition of specific TRAFs may be beneficial in one condition and harmful in others. Here, we carefully discuss the cellular expression and signaling events of TRAFs and evaluate their role in vascular inflammation and atherosclerosis. We also highlight metabolic effects of TRAFs and discuss the development of TRAF-based therapeutics in the future.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Frontiers Media S  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/  
dc.subject
TNF  
dc.subject
TRAF  
dc.subject
ATHEROSCLEROSIS  
dc.subject
IMMUNITY  
dc.subject
INFLAMMATION  
dc.subject
SIGNALING  
dc.subject.classification
Inmunología  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-07-05T12:23:43Z  
dc.identifier.eissn
2297-055X  
dc.journal.volume
9  
dc.journal.number
826630  
dc.journal.pagination
1-17  
dc.journal.pais
Suiza  
dc.journal.ciudad
Lausanne  
dc.description.fil
Fil: Gissler, Mark Colin. Albert Ludwigs University of Freiburg; Alemania  
dc.description.fil
Fil: Stachon, Peter. Albert Ludwigs University of Freiburg; Alemania  
dc.description.fil
Fil: Wolf, Dennis. Albert Ludwigs University of Freiburg; Alemania  
dc.description.fil
Fil: Marchini, Timoteo Oscar. Albert Ludwigs University of Freiburg; Alemania. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina  
dc.journal.title
Frontiers in Cardiovascular Medicine  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fcvm.2022.826630/full  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fcvm.2022.826630